Immutep (IMMP) News
NASDAQ: IMMPHealth CareBiotechnology: Pharmaceutical PreparationsUSD
3.11-0.31 (-9.06%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
IMMP news summary
We found 12 recent headlines mentioning Immutep (IMMP): 3 in the past week and 9 in the past 30 days, most often from GlobeNewswire, Nasdaq. IMMP is making an outsized move today, down 9.06% at $3.11, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Immutep Limited Reports 81.1% 12-month Disease-Free Survival in EFTISARC-NEO Phase II Trial", was published by Nasdaq on Nov 20, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Immutep headlines
- Immutep Limited Reports 81.1% 12-month Disease-Free Survival in EFTISARC-NEO Phase II TrialImmutep Limited announced new data from the investigator-initiated EFTISARC-NEO Phase II study evaluating eftilagimod alfa in combination with pembrolizumab and radiotherapy before surgery in…Nasdaq
- Immutep Posts New Survival Data From Phase 2 EFTISARC-NEO Trial;Stock Up(RTTNews) - Immutep Ltd. (IMMP), a clinical-stage biotechnology company developing immunotherapies for cancer and autoimmune diseases, announced new data from the EFTISARC-NEO Phase 2 study…NasdaqIMMP, BRK.A
- Immutep Reports Encouraging Disease-Free Survival from EFTISARC-NEO Phase II Trial in Soft Tissue SarcomaSYDNEY, AUSTRALIA, Nov. 19, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), a clinical-stage biotechnology company developing novel LAG-3…GlobeNewswire
- Immutep Further Expands United States Patent Estate for Efti-Based Combination TherapiesSYDNEY, AUSTRALIA, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapies, today announced…GlobeNewswire
- Immutep Announces Release of CTOS 2026 Abstract Reporting First Survival Data from EFTISARC-NEOSYDNEY, AUSTRALIA, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) today announced the release of an abstract reporting interim disease-free survival data and…GlobeNewswire
- Immutep Limited - Depositary Receipt Price Target Increased by 19.55% to $80.11The average one-year price target for Immutep Limited - Depositary Receipt (NASDAQGM:IMMP) has been revised to $80.11 / share. This represents an increase of 19.55% from the prior estimate of $67.01…Nasdaq
- IMP761 Late-Breaking Abstract at ACR Convergence 2026 Highlights Statistically Significant & Exposure-Dependent Inhibition of T-Cell-Driven Immune ResponsesSYDNEY, AUSTRALIA, Nov. 08, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company targeting cancer and autoimmune…GlobeNewswire
- Immutep Limited Receives A$2.16 million French R&D Tax IncentiveImmutep Limited announced that it has received a cash payment of €1.36 million (approximately A$2.16 million) from the French Government under its Crédit d’Impôt Recherche…NasdaqIMMP, BF.B
- Immutep Receives A$2.16 Mln French Tax Incentive To Support Drug Development(RTTNews) - Immutep Ltd. (IMMP), a clinical-stage immunotherapy company, said Wednesday it received cash payment of €1.36 million, approximately A$2.16 million, under the French government's…NasdaqIMMP, LEN.B
- Immutep Announces Presentation of Quality of Life Data from EFTISARC-NEO Phase II Trial at ESMO 2026Quality of life remained stable during neoadjuvant treatment with efti, pembrolizumab and radiotherapy, with statistically significant improvement after surgeryGlobeNewswire
- Immutep and Monash University Secure Further ARC Linkage Projects Funding for LAG-3 ResearchSYDNEY, AUSTRALIA, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel immunotherapies for…GlobeNewswire
- Immutep Regains Compliance with Nasdaq Minimum Bid Price RequirementSYDNEY, AUSTRALIA, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune…GlobeNewswire